DDInter1378 DDInter1376
Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Paclitaxel {u} (Compound) resembles {v} (Compound) Docetaxel
Paclitaxel {u} (Compound) treats {v} (Disease) breast cancer
Paclitaxel {u} (Compound) binds {v} (Gene) CYP3A5
Paclitaxel {u} (Compound) upregulates {v} (Gene) CDCA8
Paclitaxel {u} (Compound) is included by {v} (Pharmacologic Class) Microtubule Inhibition
Paclitaxel {u} (Compound) downregulates {v} (Gene) SCAND1
Paclitaxel {u} (Compound) causes {v} (Side Effect) Swelling face
Paclitaxel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Paclitaxel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Paclitaxel (Compound) resembles Docetaxel (Compound)
Paclitaxel (Compound) treats breast cancer (Disease)
Paclitaxel (Compound) binds CYP3A5 (Gene)
Paclitaxel (Compound) upregulates CDCA8 (Gene)
Paclitaxel (Compound) is included by Microtubule Inhibition (Pharmacologic Class)
Paclitaxel (Compound) downregulates SCAND1 (Gene)
Paclitaxel (Compound) causes Swelling face (Side Effect)
Paclitaxel may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Paclitaxel may cause a minor interaction that can limit clinical effects when taken with Delafloxacin